Answers are grounded in this paper and cite their sources.
Acute myeloid leukemia (AML) in the elderly represents a challenge to the clinician due to AML‐related and patient‐related factors that place patients at an increased risk of induction toxicity and limit treatment options. To make gains in the management of the elderly patient with AML, clinicians must focus on improved risk stratification and develop better‐tolerated active regimens.
No takes yet. Share an insight, caveat, or question.
Arellano et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: